Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis

Thrombosis and Haemostasis

Volumn 76, Issue 6, 1996, Pages 1096-1101

  Martin, Ulrich ^a   Kohnert, Ulrich ^a   Stern, Anne ^a   Popp, Fritz ^a   Fischer, Stephan ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOGEN; HEPARIN; PROTEINASE; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DOG; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; FIBRINOGEN METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE;

ANIMALS; CORONARY THROMBOSIS; DOGS; ENDOPEPTIDASES; ESCHERICHIA COLI; INJECTIONS, INTRAVENOUS; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030443158     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650712     Document Type: Review

References (21)

1. Verheijen JH, Caspers MPM, Chang GTG, de Munk GAW, Pouwels PH, Enger-Valk BE. involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525-30.
2. Dodd I, Fears R, Robinson JH. Isolation and preliminary characterization of active B-chain of recombinant tissue-type plasminogen activator. Thromb Haemost 1986; 55; 94-7.
3. Rijken DC, Groeneveld E. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3098-102.
4. Kohnert U, Hellerbrand K, Martin U, Stern A, Popp F, Fischer S. The recombinant Escherichia coli-derived protease-domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent. Fibrinolysis 1996; 10: 93-102.
5. Martin U, Kohnert U, Hellerbrand K, Stern A, Popp F, Doerge L, Stegmeier K, Müller-Beckmann B, Fischer S. Effective thrombolysis by a recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator in the rabbit model of jugular vein thrombosis. Fibrinolysis 1996; 10: 87-92.
6. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992; 19: 433-40.
7. Romson, JL, Haack, DW, Lucchesi, BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 1980; 17: 841-53.
8. Kohnert U, Rudolph R, Verheijen JH, Weening-Verhoeff FJD, Stern A, Opitz U, Martin U, Lill H, Prinz H, Lechner M, Kresse GB, Buckel P, Fischer S. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022, Protein Eng 1992; 5: 93-100.
9. Sitko GR, Ramjit DR, Stabilito H, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide - comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992; 85: 805-15.
10. Larrieu MJ, Weilland C. Utilisation de la "cephaline" dans les tests de coagulation. Rev Hematol 1957; 12: 199-210.
11. Martin U, von Möllendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-74.
12. Conover WJ, Iman RL. Rank transformation as a bridge between parametric and nonparametric statistics. Americ Statistician 1981; 35: 124-33.
13. Zerbe GO, Walker SH. A randomization test for comparison of groups of growth curves with different polynomial design matrices. Biometrics 1977; 33: 653-7.
14. Bode C, Smalling RW, Kalbfleisch J, Berg G, Odenheimer DJ, Boehm E, Weaver WD. Randomized comparison of double bolus reteplase (rPA) and front-loaded alteplase in patients with acute myocardial infarction (RAPID II). Eur Heart J 1995; 11 (abstr. suppl.): abstr. 131.
15. The INJECT Study Group. A randomized, double blind comparison of reteplase, 10 + 10 MU double bolus administration, with streptokinase in patients with acute myocardial infarction (INJECT). Lancet 1995; 346: 329-36.
16. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993; 329: 673-82.
17. Mickelson JK, Hoff PT, Homeister JW, Fantone JC, Lucchesi BR. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol 1993; 21: 502-10.
18. Kohnert U, Horsch B, Fischer S. A variant of tissue type plasminogen activator (t-PA) comprised of the kringle 2 and the protease domain shows a significant difference in the in vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed Chinese hamster ovary cells. Fibrinolysis 1993; 7: 365-72.
19. Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-4.
20. Blinc A, Kennedy SD, Bryant RG, Marder VJ, Francis CW. Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 1994; 71: 230-5.
21. Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J 1993; 65: 2622-43.